Highly potent first examples of dual aromatase-steroid sulfatase inhibitors based on a biphenyl template.

Article Details

Citation

Copy to clipboard

Woo LW, Jackson T, Putey A, Cozier G, Leonard P, Acharya KR, Chander SK, Purohit A, Reed MJ, Potter BV

Highly potent first examples of dual aromatase-steroid sulfatase inhibitors based on a biphenyl template.

J Med Chem. 2010 Mar 11;53(5):2155-70. doi: 10.1021/jm901705h.

PubMed ID

20148564 [ View in PubMed

]

Abstract

Single agents against multiple drug targets are of increasing interest. Hormone-dependent breast cancer (HDBC) may be more effectively treated by dual inhibition of aromatase and steroid sulfatase (STS). The aromatase inhibitory pharmacophore was thus introduced into a known biphenyl STS inhibitor to give a series of novel dual aromatase-sulfatase inhibitors (DASIs). Several compounds are good aromatase or STS inhibitors and DASI 20 (IC(50): aromatase, 2.0 nM; STS, 35 nM) and its chlorinated congener 23 (IC(50): aromatase, 0.5 nM; STS, 5.5 nM) are examples that show exceptional dual potency in JEG-3 cells. Both biphenyls share a para-sulfamate-containing ring B and a ring A, which contains a triazol-1-ylmethyl meta to the biphenyl bridge and para to a nitrile. At 1 mg/kg po, 20 and 23 reduced plasma estradiol levels strongly and inhibited liver STS activity potently in vivo. 23 is nonestrogenic and potently inhibits carbonic anhydrase II (IC(50) 86 nM). A complex was crystallized and its structure was solved by X-ray crystallography. This class of DASI should encourage further development toward multitargeted therapeutic intervention in HDBC.

DrugBank Data that Cites this Article

Binding Properties

Drug	Target	Property	Measurement	pH	Temperature (°C)
Anastrozole	Cytochrome P450 19A1	IC 50 (nM)	1.5	N/A	N/A	Details
Irosustat	Steryl-sulfatase	IC 50 (nM)	1.5	N/A	N/A	Details
Letrozole	Cytochrome P450 19A1	IC 50 (nM)	0.89	N/A	N/A	Details